| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
36 |
S1 |
p. vii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
36 |
S1 |
p. i
|
artikel
|
| 3 |
377eP Advanced and metastatic biliary tract cancer: Real-world evidence from a single institution in Argentina
|
Fernandez, P.
|
|
|
36 |
S1 |
p. S145
|
artikel
|
| 4 |
133eP A multicentric real-world study comparing TAS-102 alone vs TAS-102 with bevacizumab in mCRC treatment
|
Martins, T.S.C.
|
|
|
36 |
S1 |
p. S58
|
artikel
|
| 5 |
382eP Bile microbiome analysis in patients with biliary tract cancer
|
Jang, D.K.
|
|
|
36 |
S1 |
p. S147
|
artikel
|
| 6 |
375eP Biliary stenting in biliopancreatic tumors: Evidence from real-world practice
|
Pratesi, L.
|
|
|
36 |
S1 |
p. S144-S145
|
artikel
|
| 7 |
203eP Cell-free DNA (cfDNA) biomarkers and AI models for early detection of liver cancer: A systematic review and meta-analysis
|
Le, M.H.N.
|
|
|
36 |
S1 |
p. S82
|
artikel
|
| 8 |
138eP Circulating tumor DNA correlation to disease recurrence in early and advanced colorectal cancers
|
Maheshwari, S.
|
|
|
36 |
S1 |
p. S59-S60
|
artikel
|
| 9 |
218eP Clinical and molecular features of small bowel adenocarcinoma: A single-center study
|
De Grandis, M.C.
|
|
|
36 |
S1 |
p. S87-S88
|
artikel
|
| 10 |
464eP Clinical outcomes and predictors of early mortality in patients with oesophageal cancer post-stent insertion
|
Murugan, R.
|
|
|
36 |
S1 |
p. S177
|
artikel
|
| 11 |
256eP Comparative outcomes of TNT and CRT in locally advanced rectal cancer: A retrospective cohort study
|
Egea, S. Ruffini
|
|
|
36 |
S1 |
p. S100
|
artikel
|
| 12 |
504eP Comprehensive genomic profiling (CGP) of gastrointestinal cancers: A single-institution experience
|
Radic, J.
|
|
|
36 |
S1 |
p. S189
|
artikel
|
| 13 |
461eP DCF regimen as an alternative to chemoradiotherapy in esophagus squamous cell carcinoma (ESCC)
|
Turkpenova, I.
|
|
|
36 |
S1 |
p. S176-S177
|
artikel
|
| 14 |
137eP Diagnostics of the level of immunoglobulins (Ig), tumor markers (TM) and proteins in the plasma and supernatant before and after treatment in patients with colorectal cancer (CRC) taking into account modern approaches to proteomics
|
Turkpenova,
|
|
|
36 |
S1 |
p. S59
|
artikel
|
| 15 |
371eP Distinct microbiome composition and reduced interactions in patients with pancreatic cancer
|
Seo, W.
|
|
|
36 |
S1 |
p. S144
|
artikel
|
| 16 |
374eP Effects of perioperative exercise therapy in patients with pancreatic cancer: A systematic review and meta-analysis
|
Sato, N.
|
|
|
36 |
S1 |
p. S144
|
artikel
|
| 17 |
131eP Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment
|
Han, L.
|
|
|
36 |
S1 |
p. S57
|
artikel
|
| 18 |
376eP Endoscopic vs percutaneous biliary decompression in malignant jaundice: Impact on postoperative complications and hospital stay
|
Manukyan, M.
|
|
|
36 |
S1 |
p. S145
|
artikel
|
| 19 |
509eP Evaluating the efficacy of atorvastatin in mitigating radiotherapy-induced gastrointestinal toxicity: A randomized controlled trial
|
Elhaie, M.
|
|
|
36 |
S1 |
p. S190-S191
|
artikel
|
| 20 |
463eP Evaluation of efficacy of definitive chemo-radiation in inoperable carcinoma esophagus
|
Vuba, S.P.
|
|
|
36 |
S1 |
p. S177
|
artikel
|
| 21 |
474eP Evaluation of nutritional support strategies in metastatic gastric cancer patients undergoing first-line treatments
|
Nappo, F.
|
|
|
36 |
S1 |
p. S179
|
artikel
|
| 22 |
130eP From evidence to practice: A multicenter real-world study and meta-analysis of immunotherapy in MSS/MSI-L colorectal cancer
|
Gou, Y.T.
|
|
|
36 |
S1 |
p. S57
|
artikel
|
| 23 |
476eP Global impact and value of disability-adjusted life years from esophageal and gastric cancers: A cancer-specific multicountry analysis (2000-2021)
|
Ruiz, R. Aste
|
|
|
36 |
S1 |
p. S179
|
artikel
|
| 24 |
208eP Hsa_circ_0000284 (circHIPK3) and Hsa_circ_0001944 (circBCBM) are novel biomarkers for early detection of HCV-induced hepatocellular carcinoma
|
Youness, R.A.
|
|
|
36 |
S1 |
p. S84
|
artikel
|
| 25 |
254eP Immunotherapy in dMMR/MSI locally advanced rectal cancer: A real-world retrospective study from an Argentine center
|
Maquieira, J.
|
|
|
36 |
S1 |
p. S99
|
artikel
|
| 26 |
369eP Impact of ascites on treatment outcomes of Nal-IRI+5-FU/LV in patients with pancreatic cancer with peritoneal dissemination
|
Inoue, K.
|
|
|
36 |
S1 |
p. S143
|
artikel
|
| 27 |
468eP Impact of biomarker-guided targeted therapy on survival in advanced gastric adenocarcinoma: A single-center retrospective analysis
|
Abad, C. Blanco
|
|
|
36 |
S1 |
p. S178
|
artikel
|
| 28 |
506eP Impact of CARG-guided dose adjustment of anticancer therapy on adverse events in Chinese elderly cancer patients: A prospective study
|
Ge, Y.
|
|
|
36 |
S1 |
p. S190
|
artikel
|
| 29 |
472eP Impact of neoadjuvant chemotherapy on nutritional status and its influence on clinical outcomes in resectable gastric cancer
|
Rodriguez, D.I. Rosero
|
|
|
36 |
S1 |
p. S178
|
artikel
|
| 30 |
460eP Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: A multicenter retrospective study
|
Guven, D.C.
|
|
|
36 |
S1 |
p. S176
|
artikel
|
| 31 |
56eP Liver transplantation or hepatic arterial infusion for unresectable colorectal liver metastases: A meta-analysis of reconstructed single-arm survival data
|
Jones, O.
|
|
|
36 |
S1 |
p. S31
|
artikel
|
| 32 |
207eP LncRNA sONE: A novel therapeutic hub in hepatocellular carcinoma restoring NO homeostasis and NK cell activation via miR-34a/ULBP2 regulation
|
Hozayen, S.
|
|
|
36 |
S1 |
p. S83
|
artikel
|
| 33 |
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)
|
Shah, N.M.
|
|
|
36 |
S1 |
p. S134
|
artikel
|
| 34 |
135eP Nutrition and chemotherapy tolerance in Moroccan patients with metastatic colorectal cancer
|
Kriouile, S.
|
|
|
36 |
S1 |
p. S59
|
artikel
|
| 35 |
134eP Observed survival following treatment with leronlimab in patients with metastatic colorectal cancer
|
Baron, A.
|
|
|
36 |
S1 |
p. S58-S59
|
artikel
|
| 36 |
255eP Overall response to total neoadjuvant therapy (TNT) followed by surgery in locally advanced rectal cancer: A three and a half year experience at a tertiary level hospital in Bangladesh
|
Hossain, N.T.
|
|
|
36 |
S1 |
p. S100
|
artikel
|
| 37 |
378eP Pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An initial analysis of real-world experience
|
Sasaki, M.
|
|
|
36 |
S1 |
p. S145-S146
|
artikel
|
| 38 |
380eP Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis
|
Tissera, N.S.
|
|
|
36 |
S1 |
p. S146
|
artikel
|
| 39 |
367eP Phase II trial of FTD/TPI and nal-IRI in advanced PDAC
|
Hannan, L.
|
|
|
36 |
S1 |
p. S142
|
artikel
|
| 40 |
219eP Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: A retrospective cohort study
|
Zhang, H.
|
|
|
36 |
S1 |
p. S88
|
artikel
|
| 41 |
205eP Prognostic influence of baseline ALBI grade on treatment outcomes in hepatocellular carcinoma patients receiving lenvatinib
|
Babu, M.
|
|
|
36 |
S1 |
p. S83
|
artikel
|
| 42 |
217eP Prognostic role of Ki-67 in advanced GEP-NET G2: A retrospective analysis with ROC curve evaluation
|
Diaz, W.E. Cruz
|
|
|
36 |
S1 |
p. S87
|
artikel
|
| 43 |
370eP Prognostic significance of CA19-9 before conversion surgery for patients with initially unresectable pancreatic cancer
|
Kobayashi, S.
|
|
|
36 |
S1 |
p. S143
|
artikel
|
| 44 |
132eP Prognostic uncertainty in refractory mCRC: Evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world setting
|
Frazão, P.
|
|
|
36 |
S1 |
p. S58
|
artikel
|
| 45 |
141eP Prognostic value of circulating tumor DNA (ctDNA) in colorectal cancer: A systematic review and meta-analysis
|
Adhikari, S.
|
|
|
36 |
S1 |
p. S60-S61
|
artikel
|
| 46 |
507eP Psychological distress and overload prevalence in Latin American caregivers of colorectal cancer
|
Carbajal-López, B.
|
|
|
36 |
S1 |
p. S190
|
artikel
|
| 47 |
241eP Rationale for selecting the definitive stage of ultra-low anterior resection of the rectum
|
Gordiichuk, M.
|
|
|
36 |
S1 |
p. S95
|
artikel
|
| 48 |
206eP Real-world efficacy and safety of anlotinib in hepatocellular carcinoma previously treated with immune checkpoint inhibitors
|
Shang, C.
|
|
|
36 |
S1 |
p. S83
|
artikel
|
| 49 |
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers
|
Chen, J.
|
|
|
36 |
S1 |
p. S189-S190
|
artikel
|
| 50 |
368eP Real-world outcomes of nanoliposomal irinotecan plus fluorouracil in second-line treatment of advanced pancreatic cancer: A multicenter retrospective study from Thailand
|
Thambamroong, T.
|
|
|
36 |
S1 |
p. S142-S143
|
artikel
|
| 51 |
466eP Real-world outcomes of nivolumab-based chemoimmunotherapy in patients with advanced gastric cancer
|
Kim, T-H.
|
|
|
36 |
S1 |
p. S177
|
artikel
|
| 52 |
467eP Real-world outcomes of nivolumab plus chemotherapy in advanced gastric cancer with CPS 1–5: A single-center retrospective cohort study from Argentina
|
Blanco, V.E.
|
|
|
36 |
S1 |
p. S178
|
artikel
|
| 53 |
379eP Real-world outcomes of second-line chemotherapy in biliary tract cancer following chemo-immunotherapy: Insights from a single Italian institute
|
Di Giacomo, E.
|
|
|
36 |
S1 |
p. S146
|
artikel
|
| 54 |
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)
|
Wang, Z.
|
|
|
36 |
S1 |
p. S60
|
artikel
|
| 55 |
335eP Real-world study of immunotherapy and trastuzumab for HER2-positive biliary tract cancers
|
Muddu, V.K.
|
|
|
36 |
S1 |
p. S131
|
artikel
|
| 56 |
154eP Real-world systemic treatment patterns and outcomes in patients with hepatocellular carcinoma (HCC): Experience from the UK South East Midlands oncology centre, 2019-2024
|
Suwaidan, A.A.M.
|
|
|
36 |
S1 |
p. S66
|
artikel
|
| 57 |
250eP Rectal cancer care in LMIC: Insights, challenges, and outcomes
|
Abbaraju, H.
|
|
|
36 |
S1 |
p. S98
|
artikel
|
| 58 |
143eP Rethinking adjuvant chemotherapy in colon cancer patients aged ≥65: Survival and prognostic factors
|
Birsin, Z.
|
|
|
36 |
S1 |
p. S61
|
artikel
|
| 59 |
209eP RPL41 promotes HCC metastasis via transcription factors RUNX2-mediated EMT mechanism
|
Hua, Z.A.
|
|
|
36 |
S1 |
p. S84
|
artikel
|
| 60 |
142eP The oncological safety of single-incision laparoscopic surgery versus conventional laparoscopic surgery in colorectal cancer: A pilot study
|
Baker, L.
|
|
|
36 |
S1 |
p. S61
|
artikel
|
| 61 |
373eP The role of radiotherapy in pancreatic cancer: Retrospective analysis of a tertiary center
|
Ferrão, A.R.
|
|
|
36 |
S1 |
p. S144
|
artikel
|
| 62 |
381eP Trace elements in serum as potential biomarkers in biliary tract cancers
|
Rebersek, M.
|
|
|
36 |
S1 |
p. S146-S147
|
artikel
|
| 63 |
204eP Validation of the ALICE model for predicting postoperative ascites after liver resection in hepatocellular carcinoma: A comparison with ALBI and Child-Pugh classification
|
Nakamura, M.
|
|
|
36 |
S1 |
p. S82-S83
|
artikel
|
| 64 |
140eP Value of baseline modified Glasgow prognostic score and sarcopenia as predictive tools in colorectal cancer prognosis
|
Khemiri, W.
|
|
|
36 |
S1 |
p. S60
|
artikel
|
| 65 |
473eP When the end comes too soon: Adjuvant chemotherapy dropout in gastric cancer and the promise of TNT
|
Etxebarría, A. Uriarte
|
|
|
36 |
S1 |
p. S178-S179
|
artikel
|
| 66 |
ESMO
|
|
|
|
36 |
S1 |
p. v
|
artikel
|
| 67 |
221eTiP A single-blinded, randomised controlled trial to evaluate the non-inferiority of HIPEC with low-dose versus high-dose mitomycin C in the treatment of pseudomyxoma peritonei from perforated epithelial mucinous tumours of the appendix
|
Ewings, S.
|
|
|
36 |
S1 |
p. S88
|
artikel
|
| 68 |
510eTiP Consensus for nutritional management in pancreatobiliary and upper gastrointestinal cancer: A Delphi study
|
Pacheco-Barcia, V.E.
|
|
|
36 |
S1 |
p. S191
|
artikel
|
| 69 |
387eTiP DOVIPA: A phase II study with safety run-in of mFOLFIRINOX, dostarlimab, and oral vitamin D in metastatic pancreatic cancer with translational research on resistance mechanisms
|
Benmaziane, A. Teillet
|
|
|
36 |
S1 |
p. S149
|
artikel
|
| 70 |
478eTiP UCCL-IKF-NeoART: An international phase Ib/II trial investigating trastuzumab-deruxtecan (T-DXd) combined with neoadjuvant chemotherapy (Ctx) for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)
|
Stocker, G.
|
|
|
36 |
S1 |
p. S180
|
artikel
|
| 71 |
GI Congress Officers
|
|
|
|
36 |
S1 |
p. vi
|
artikel
|
| 72 |
LBA1 Dynamic circulating tumor DNA methylation monitoring guiding postoperative surveillance in non-metastatic colorectal cancer: Interim analysis of FIND trial
|
Peng, J.
|
|
|
36 |
S1 |
p. S1
|
artikel
|
| 73 |
LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
|
Al-Batran, S-E.
|
|
|
36 |
S1 |
p. S150-S151
|
artikel
|
| 74 |
LBA3 PANOVA-3: Pain and quality of life (QoL) outcomes with Tumor Treating Fields (TTFields) therapy in patients with locally advanced pancreatic adenocarcinoma (LAPC)
|
Mercade, T. Macarulla
|
|
|
36 |
S1 |
p. S101
|
artikel
|
| 75 |
LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)
|
Dong, J.
|
|
|
36 |
S1 |
p. S62
|
artikel
|
| 76 |
260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
|
Dean, A.
|
|
|
36 |
S1 |
p. S102
|
artikel
|
| 77 |
261MO A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations
|
Ahn, D.
|
|
|
36 |
S1 |
p. S102-S103
|
artikel
|
| 78 |
259MO BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma
|
Weinberg, B.A.
|
|
|
36 |
S1 |
p. S101-S102
|
artikel
|
| 79 |
390MO Definitive chemoradiotherapy for adenocarcinoma of the esophagus: A Dutch population-based cohort
|
Gangaram-Panday, S.
|
|
|
36 |
S1 |
p. S152-S153
|
artikel
|
| 80 |
149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study
|
Cheng, Q.
|
|
|
36 |
S1 |
p. S63
|
artikel
|
| 81 |
393MO Overall survival in germline CDH1 pathogenic variant (PV) carriers: A multicenter comparative analysis study
|
Lapena, M. Cruellas
|
|
|
36 |
S1 |
p. S154
|
artikel
|
| 82 |
7MO Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): Final results of the randomised phase II PANIRINOX-UCGI28 study
|
Mazard, T.
|
|
|
36 |
S1 |
p. S6-S7
|
artikel
|
| 83 |
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
|
Fernandez, E. Elez
|
|
|
36 |
S1 |
p. S181
|
artikel
|
| 84 |
391MO Phase III randomized IRIGA trial of FOLFIRINOX versus mFOLFOX6 as first-line treatment for patients with HER2-negative gastric and gastroesophageal adenocarcinoma
|
Gavrilova, D.
|
|
|
36 |
S1 |
p. S153
|
artikel
|
| 85 |
223MO Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study
|
Borelli, B.
|
|
|
36 |
S1 |
p. S89-S90
|
artikel
|
| 86 |
262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study
|
Bridgewater, J.A.
|
|
|
36 |
S1 |
p. S103
|
artikel
|
| 87 |
388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
|
Klempner, S.J.
|
|
|
36 |
S1 |
p. S151-S152
|
artikel
|
| 88 |
6MO Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
|
Arnold, D.
|
|
|
36 |
S1 |
p. S5-S6
|
artikel
|
| 89 |
392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial
|
Moehler, M.
|
|
|
36 |
S1 |
p. S153
|
artikel
|
| 90 |
150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
|
Chan, S.L.
|
|
|
36 |
S1 |
p. S63-S64
|
artikel
|
| 91 |
389MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis
|
Van Cutsem, E.
|
|
|
36 |
S1 |
p. S152
|
artikel
|
| 92 |
222MO Tumor immune microenvironment and survival outcome following preoperative chemoradiotherapy in locally advanced rectal cancer: Results from the STAR-01 study cohort
|
Negri, F.
|
|
|
36 |
S1 |
p. S89
|
artikel
|
| 93 |
Notice and Disclaimer
|
|
|
|
36 |
S1 |
p. iii
|
artikel
|
| 94 |
5O A double-blind placebo-controlled randomized phase II clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies
|
Purim, O.
|
|
|
36 |
S1 |
p. S4-S5
|
artikel
|
| 95 |
3O Association of ctDNA clearance with disease-free survival, safety, and quality of life from ctDNA-directed therapy: Findings from the ALTAIR study
|
Kotaka, M.
|
|
|
36 |
S1 |
p. S3-S4
|
artikel
|
| 96 |
2O Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance
|
Dasari, N.A.
|
|
|
36 |
S1 |
p. S3
|
artikel
|
| 97 |
4O Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial
|
Ciracì, P.
|
|
|
36 |
S1 |
p. S4
|
artikel
|
| 98 |
1O Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW
|
Fernandez, E. Elez
|
|
|
36 |
S1 |
p. S1-S3
|
artikel
|
| 99 |
148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW
|
Sangro, B.
|
|
|
36 |
S1 |
p. S62-S63
|
artikel
|
| 100 |
313P ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer
|
Zhang, Y.
|
|
|
36 |
S1 |
p. S122
|
artikel
|
| 101 |
43P A canadian real-world evidence study of panitumumab with encorafenib in BRAF V600E mutated metastatic colorectal cancer (mCRC)
|
Cheung, W.Y.
|
|
|
36 |
S1 |
p. S27
|
artikel
|
| 102 |
268P Activating immune engagement against pancreatic ductal adenocarcinoma (PDAC): Effect of LSTA-1 and durvalumab on tumour-infiltrating lymphocytes (TILs)
|
Talbot, A.
|
|
|
36 |
S1 |
p. S106
|
artikel
|
| 103 |
95P Adding quantitation to a tumor-informed molecular residual disease (MRD) assay to measure circulating tumor DNA as a marker of recurrence risk in patients with stage III colorectal cancer (CRC)
|
Schoen, R.E.
|
|
|
36 |
S1 |
p. S46-S47
|
artikel
|
| 104 |
277P Additional high-intensity focused ultrasound (HIFU) improves survival in patients with advanced pancreatic cancer undergoing palliative chemotherapy: A large-cohort comparative study
|
Carmona, M.A. Gonzalez
|
|
|
36 |
S1 |
p. S109
|
artikel
|
| 105 |
226P Adebrelimab combined with short-course radiotherapy and CAPOX as total neoadjuvant therapy for pMMR locally advanced rectal cancer: Interim results
|
Jing, C.
|
|
|
36 |
S1 |
p. S90-S91
|
artikel
|
| 106 |
357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial
|
Goetze, T.O.
|
|
|
36 |
S1 |
p. S140
|
artikel
|
| 107 |
301P Adjuvant chemotherapy of S-1 plus metformin versus S-1 for radical resection of pancreatic cancer: Multicenter randomized phase II trial
|
Furukawa, M.
|
|
|
36 |
S1 |
p. S118
|
artikel
|
| 108 |
103P Age cut-off for oxaliplatin efficacy in stage II/III colorectal cancer
|
Kang, S.
|
|
|
36 |
S1 |
p. S49
|
artikel
|
| 109 |
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings
|
Claessens, A.
|
|
|
36 |
S1 |
p. S120
|
artikel
|
| 110 |
49P A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer
|
Lai, K.Y.
|
|
|
36 |
S1 |
p. S29
|
artikel
|
| 111 |
99P A multi-marker panel for CMS-based molecular classification of colorectal cancer in a Latin American cohort
|
Quiroz, A.
|
|
|
36 |
S1 |
p. S48
|
artikel
|
| 112 |
280P Analysis of treatment outcome in pancreatic ductal adenocarcinoma patients harboring germline pathogenic variants in DNA damage repair genes
|
Carconi, C.
|
|
|
36 |
S1 |
p. S110
|
artikel
|
| 113 |
341P Angiotensin system inhibitors use and its impact on survival in cholangiocarcinoma patients
|
Keum, J.
|
|
|
36 |
S1 |
p. S133-S134
|
artikel
|
| 114 |
264P An open-label, uncontrolled study of magrolimab (ONO-7913) and nivolumab (ONO-4538) in combination with standard modified-FOLFIRINOX chemotherapy as first-line treatment in patients with metastatic pancreatic cancer
|
Ueno, M.
|
|
|
36 |
S1 |
p. S104
|
artikel
|
| 115 |
32P A novel imaging biomarker, quantitative vessel tortuosity, captures the antiangiogenic effect of fruquintinib in metastatic colorectal cancer
|
Lonardi, S.
|
|
|
36 |
S1 |
p. S19
|
artikel
|
| 116 |
98P A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth
|
Zhong, Y.
|
|
|
36 |
S1 |
p. S47-S48
|
artikel
|
| 117 |
213P Anti-angiogenics combined with chemotherapy improve survival in the first-line treatment of patients with metastatic small bowel adenocarcinoma: A retrospective study by the AGEO
|
Boisteau, E.
|
|
|
36 |
S1 |
p. S86
|
artikel
|
| 118 |
39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs)
|
Raimondi, A.
|
|
|
36 |
S1 |
p. S24
|
artikel
|
| 119 |
319P Antitumour activity and safety of first-line zanidatamab + cisplatin-gemcitabine in patients with HER2-expressing biliary tract cancer (BTC)
|
Oh, D-Y.
|
|
|
36 |
S1 |
p. S123-S124
|
artikel
|
| 120 |
263P A phase Ib dose-escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer (COMBAT-PC)
|
Pant, S.
|
|
|
36 |
S1 |
p. S104
|
artikel
|
| 121 |
174P A phase II, non-randomized, single-arm, translational study of cabozantinib for patients with hepatocellular carcinoma (HCC) refractory to first-line treatment (the IKF-t018 AURORA trial)
|
Vogel, A.
|
|
|
36 |
S1 |
p. S73
|
artikel
|
| 122 |
163P Are clinical factors useful for identifying primary progressors (PP) in patients (pts) with hepatocellular carcinoma (HCC) undergoing first-line treatment with atezolizumab plus bevacizumab (AB)? Analysis from the Italian ARTE database
|
Cesario, S.
|
|
|
36 |
S1 |
p. S70-S71
|
artikel
|
| 123 |
273P A retrospective single-center analysis of treatment strategies and real-world outcomes in locally advanced pancreatic cancer
|
Beltran, J. Sanz
|
|
|
36 |
S1 |
p. S107
|
artikel
|
| 124 |
399P ARL5B drives esophageal squamous cell carcinoma progression via ROCK1-SREBP1-mediated metabolic reprogramming
|
Ma, X.
|
|
|
36 |
S1 |
p. S156
|
artikel
|
| 125 |
459P Artificial intelligence in action: A meta-analysis of AI-assisted endoscopy for upper GI cancers
|
Abdelghany, A.
|
|
|
36 |
S1 |
p. S176
|
artikel
|
| 126 |
396P A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy
|
Kuo, H-Y.
|
|
|
36 |
S1 |
p. S155
|
artikel
|
| 127 |
177P Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310)
|
Kim, R.
|
|
|
36 |
S1 |
p. S74-S75
|
artikel
|
| 128 |
499P Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy
|
Yeo, W.
|
|
|
36 |
S1 |
p. S187-S188
|
artikel
|
| 129 |
158P Atezolizumab plus bevacizumab as first-line therapy in unresectable HCC: Final analysis from phase IIIb AMETHISTA study
|
Rimassa, L.
|
|
|
36 |
S1 |
p. S67-S68
|
artikel
|
| 130 |
159P ATHECA: Final safety and efficacy analysis of a phase IIIb study of atezolizumab + bevacizumab in Spanish patients with unresectable HCC
|
Monzon, M.E. Reig
|
|
|
36 |
S1 |
p. S68-S69
|
artikel
|
| 131 |
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing systemic treatment
|
Valentí, V.
|
|
|
36 |
S1 |
p. S188
|
artikel
|
| 132 |
65P BETTER study: An open-label, single-arm trial of tislelizumab, bevacizumab, TAS102, and SBRT as third-line therapy for MSS/pMMR metastatic colorectal cancer
|
Zhang, Q.
|
|
|
36 |
S1 |
p. S35-S36
|
artikel
|
| 133 |
195P Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma
|
Chen, X.
|
|
|
36 |
S1 |
p. S80
|
artikel
|
| 134 |
343P Body mass index and somatic variants in biliary tract cancers
|
Al Mahmasani, L.
|
|
|
36 |
S1 |
p. S134-S135
|
artikel
|
| 135 |
8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
|
Schlechter, B.L.
|
|
|
36 |
S1 |
p. S7-S8
|
artikel
|
| 136 |
36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6
|
Yoshino, T.
|
|
|
36 |
S1 |
p. S21-S22
|
artikel
|
| 137 |
234P Cardiotoxicity of total neoadjuvant treatment in locally advanced rectal cancer
|
Valzano, M.
|
|
|
36 |
S1 |
p. S93
|
artikel
|
| 138 |
310P Cascade testing in families with hereditary pancreatic cancer
|
Lopez, E. Varga
|
|
|
36 |
S1 |
p. S121
|
artikel
|
| 139 |
265P CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 24-month follow up and dose characterization from the OPTIMIZE-1 study
|
Lambert, A.
|
|
|
36 |
S1 |
p. S105
|
artikel
|
| 140 |
282P CDKN2A mutations as prognostic and predictive factor in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center study
|
Cosmai, A.
|
|
|
36 |
S1 |
p. S111
|
artikel
|
| 141 |
356P CD80 tumour-expression predicts benefits from capecitabine in the BILCAP phase III randomized adjuvant trial
|
Rofei, M.
|
|
|
36 |
S1 |
p. S139-S140
|
artikel
|
| 142 |
115P Changes in surgical and oncological characteristics of early-onset and late-onset colorectal cancers over five-year periods: A single-center 10-year experience
|
Mutlu, A.U.
|
|
|
36 |
S1 |
p. S53
|
artikel
|
| 143 |
297P Changes in the microbiome during treatment with chemo-immunotherapy in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC): A prospective study
|
Comito, O.R.
|
|
|
36 |
S1 |
p. S117
|
artikel
|
| 144 |
352P Characterization of cholangiocarcinoma tumor microenvironment at spatial resolution identifies two main multicellular communities
|
Teixido, M.
|
|
|
36 |
S1 |
p. S138
|
artikel
|
| 145 |
87P Characterization, though multidimensional analyses, of different subsets of immune cells and soluble molecules in the peripheral blood of colorectal cancer patients to identify candidate biomarkers for patients’ clinical outcome
|
Rasul, K.I.
|
|
|
36 |
S1 |
p. S44
|
artikel
|
| 146 |
424P Chemotherapy (SOX) plus tisleizumab in gastric cancer patients with liver metastasis: The first report from a multi-center phase II study
|
Kang, M.
|
|
|
36 |
S1 |
p. S166
|
artikel
|
| 147 |
19P Circulating tumor DNA (ctDNA) dynamics predict clinical recurrence in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment
|
Studiale, V.
|
|
|
36 |
S1 |
p. S13
|
artikel
|
| 148 |
408P Claudin18.2 expression and its association with immunotherapy outcomes in gastroesophageal adenocarcinoma
|
Brage, E. Terán
|
|
|
36 |
S1 |
p. S160
|
artikel
|
| 149 |
22P Clinical and genomics characterization of PIK3CA-mutant (mPIK3CA) metastatic colorectal cancer (mCRC) at a Brazilian cancer center: A real-world data analysis
|
Santana, L.G.
|
|
|
36 |
S1 |
p. S15
|
artikel
|
| 150 |
178P Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
|
Lombardi, P.
|
|
|
36 |
S1 |
p. S75
|
artikel
|
| 151 |
75P Clinical and molecular characteristics of young onset colorectal cancers
|
Akoury, E.R.
|
|
|
36 |
S1 |
p. S40
|
artikel
|
| 152 |
309P Clinical features and survival estimates of pancreatic cancer in patients with chronic calcific pancreatitis
|
A.H. Mirsa,
|
|
|
36 |
S1 |
p. S120-S121
|
artikel
|
| 153 |
278P Clinical impact of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study in Japan
|
Hayashi, M.
|
|
|
36 |
S1 |
p. S109
|
artikel
|
| 154 |
35P Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13)
|
Sunakawa, Y.
|
|
|
36 |
S1 |
p. S20
|
artikel
|
| 155 |
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada
|
Yuan, L.
|
|
|
36 |
S1 |
p. S98-S99
|
artikel
|
| 156 |
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)
|
Genovesi, V.
|
|
|
36 |
S1 |
p. S118
|
artikel
|
| 157 |
243P Clinical performance of Signatera genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program
|
Dasari, N.A.
|
|
|
36 |
S1 |
p. S96
|
artikel
|
| 158 |
249P Clinical presentation and histopathological characteristics of rectal cancer in a low and middle income country
|
Aje, E.A.
|
|
|
36 |
S1 |
p. S98
|
artikel
|
| 159 |
15P Clinical relevance of tumor fraction assessment from circulating tumor DNA and RNF43 mutations as predictors of anti-BRAF/EGFR outcomes in metastatic colorectal cancer
|
Toledo, R.D.A.
|
|
|
36 |
S1 |
p. S11
|
artikel
|
| 160 |
286P Clinical significance of ctDNA conversion during systemic therapy in metastatic pancreatic cancer: Insights from ctDNA-RECIST
|
Steiniche, M.M.
|
|
|
36 |
S1 |
p. S112
|
artikel
|
| 161 |
17P Clinical utility of liquid biopsy in patients with metastatic non-resectable CRC
|
Yousef, M.M.G.
|
|
|
36 |
S1 |
p. S12
|
artikel
|
| 162 |
403P Clinical utility of primary prophylactic filgrastim in resectable esophageal cancer treated with neoadjuvant FLOT therapy
|
Tauchi, J.
|
|
|
36 |
S1 |
p. S157-S158
|
artikel
|
| 163 |
93P Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA
|
Nakamura, Y.
|
|
|
36 |
S1 |
p. S46
|
artikel
|
| 164 |
90P Clinicopathological distinctions between MSS and MSI-H colorectal tumors in patients with Lynch syndrome
|
Lanade, O.
|
|
|
36 |
S1 |
p. S45
|
artikel
|
| 165 |
439P Clinicopathological features, molecular profiling and survival outcomes in young-onset gastric cancer: A retrospective cohort study
|
García de Quevedo Suero, C.
|
|
|
36 |
S1 |
p. S171
|
artikel
|
| 166 |
285P Clonal hematopoiesis as a pitfall in pancreatic ductal adenocarcinoma molecular profiling
|
Croitoru-Cazacu, I.M.
|
|
|
36 |
S1 |
p. S112
|
artikel
|
| 167 |
83P Colorectal cancer in the young and old patients: A 30-year analysis at the Modena Cancer Center
|
Medici, B.
|
|
|
36 |
S1 |
p. S42
|
artikel
|
| 168 |
18P Combined analysis of plasmatic mutant allele fraction (pMAF) and RECISTv1.1 in MSI metastatic colorectal cancer (mCRC) treated with immune-checkpoint inhibitors (ICI)
|
Montana, F.J. Ros
|
|
|
36 |
S1 |
p. S12-S13
|
artikel
|
| 169 |
194P Combined hepatocellular cholangiocarcinoma: A population-based retrospective study
|
Kokudo, T.
|
|
|
36 |
S1 |
p. S80
|
artikel
|
| 170 |
55P Combining systemic treatments and multiple surgical resections in oligometastatic colorectal cancer patients: A referral center experience
|
Trovato, G.
|
|
|
36 |
S1 |
p. S31
|
artikel
|
| 171 |
78P Comparative analysis of molecular alterations in colorectal cancer patients under 50 and over 50: Insights from next-generation sequencing
|
Pena, M. Balsa
|
|
|
36 |
S1 |
p. S41
|
artikel
|
| 172 |
358P Comparative effectiveness of adjuvant chemotherapy regimens in resected biliary tract cancer: A single-center retrospective cohort study
|
Lin, W-Y.
|
|
|
36 |
S1 |
p. S140
|
artikel
|
| 173 |
160P Comparative effectiveness of atezolizumab plus bevacizumab versus tremelimumab plus durvalumab in a real-world setting
|
Lo Prinzi, F.
|
|
|
36 |
S1 |
p. S69
|
artikel
|
| 174 |
417P Comparative efficacy and safety of tislelizumab (TIS) vs other anti–PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): A network meta-analysis (NMA)
|
Maqueda, M. Alsina
|
|
|
36 |
S1 |
p. S163-S164
|
artikel
|
| 175 |
76P Comparative molecular and clinical landscape of early- vs late-onset advanced colorectal cancer
|
Rodriguez, D.I. Rosero
|
|
|
36 |
S1 |
p. S40
|
artikel
|
| 176 |
183P Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population
|
Li, J.
|
|
|
36 |
S1 |
p. S76-S77
|
artikel
|
| 177 |
351P Comprehensive genomic profiling and efficacy data in patients with advanced biliary tract cancer treated in first-line with chemo-immunotherapy combination: A real world experience
|
Nacca, V.
|
|
|
36 |
S1 |
p. S138
|
artikel
|
| 178 |
28P Comprehensive genomic profiling (CGP) of colorectal cancer ovarian metastases
|
Chiofalo, L.
|
|
|
36 |
S1 |
p. S16-S17
|
artikel
|
| 179 |
482P Comprehensive genomic profiling in routine clinical practice: Performance and clinical utility for patients with gastro-intestinal cancers
|
Maddalena, G.
|
|
|
36 |
S1 |
p. S182
|
artikel
|
| 180 |
14P Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: Subgroup analysis of the ROME trial
|
Cremolini, C.
|
|
|
36 |
S1 |
p. S10-S11
|
artikel
|
| 181 |
410P Comprehensive molecular and immunological characterization of CLDN18.2 in esophageal and esophagogastric junction carcinoma (EEJC)
|
Malla, M.
|
|
|
36 |
S1 |
p. S161
|
artikel
|
| 182 |
415P Comprehensive nutritional assessment in patients with locally advanced gastroesophageal adenocarcinoma in the perioperative setting: A sub-analysis of a prospective observational study
|
Boldrini, L.
|
|
|
36 |
S1 |
p. S163
|
artikel
|
| 183 |
435P Conversion surgery in metastatic gastric cancer: A retrospective analysis
|
Gavrilova, D.
|
|
|
36 |
S1 |
p. S170
|
artikel
|
| 184 |
61P Correlation between survival outcomes and duration of sequential treatment with regorafenib and trifluridine/tipiracil for refractory metastatic colorectal cancer: Results from the multicenter retrospective ReTrITA study
|
Signorelli, C.
|
|
|
36 |
S1 |
p. S34
|
artikel
|
| 185 |
414P Correlation between tumor regression grades (TRG) and overall survival in locally advanced resectable gastroesophageal adenocarcinoma (LAR-GEA): Real-world data (RWD) analysis
|
Gonzalez-Aguado, L.
|
|
|
36 |
S1 |
p. S162
|
artikel
|
| 186 |
245P Correlation of pathological complete response (pCR) to survival outcomes in locally advanced rectal cancer and predictors to it: A retrospective study
|
Khalil, K.A.
|
|
|
36 |
S1 |
p. S96-S97
|
artikel
|
| 187 |
101P Cost-effectiveness of liquid biopsy in stage II colon cancer: A real-world analysis
|
Martelli, V.
|
|
|
36 |
S1 |
p. S48-S49
|
artikel
|
| 188 |
162P Crossing the 3-year mark: Real-world outcomes of atezolizumab - bevacizumab for advanced HCC
|
Tovoli, F.
|
|
|
36 |
S1 |
p. S70
|
artikel
|
| 189 |
128P Cytotoxicity of arfolitixorin versus leucovorin (LEU) with 5-fluorouracil (5FU) and oxaliplatin in colorectal cancer (CRC) patient-derived tumoroids (PDTs)
|
Eide, P.
|
|
|
36 |
S1 |
p. S56-S57
|
artikel
|
| 190 |
74P Deciphering the proteomic landscape of pregnancy-associated colorectal cancer
|
Ben-Aharon, I.
|
|
|
36 |
S1 |
p. S39-S40
|
artikel
|
| 191 |
430P Decoding the responsive and resistant features to the claudin18.2-specific CAR T cell CT041 in gastric cancer: An exploratory biomarker analysis of the phase I clinical trial
|
Peng, H.
|
|
|
36 |
S1 |
p. S168-S169
|
artikel
|
| 192 |
104P Deep learning-based automated prognostic stratification through analysis of invasive margin T-cell infiltrates in localized colon cancer
|
Lecuelle, J.
|
|
|
36 |
S1 |
p. S49-S50
|
artikel
|
| 193 |
434P Deep learning-based CT segmentation methods for radiomics in pembrolizumab-treated gastric cancer
|
Han, T.
|
|
|
36 |
S1 |
p. S169-S170
|
artikel
|
| 194 |
121P Deep learning can predict MSI/MMR status from primary and metastatic colorectal tissue slides
|
Arslan, S.
|
|
|
36 |
S1 |
p. S55-S56
|
artikel
|
| 195 |
253P Defining fibroblast niches in rectal cancer
|
Tyrrell, H.E.J.
|
|
|
36 |
S1 |
p. S99
|
artikel
|
| 196 |
112P Defining who benefits: Adjuvant treatment patterns and survival outcomes in stage II colon cancer - A multicenter real-world analysis
|
Pina-Cabral, T.
|
|
|
36 |
S1 |
p. S52
|
artikel
|
| 197 |
397P Definition and treatment of oligometastatic esophageal squamous cell carcinoma according to multidisciplinary tumor boards in Japan: OMESC-2 study
|
Nomura, M.
|
|
|
36 |
S1 |
p. S155-S156
|
artikel
|
| 198 |
31P Derived neutrophil-to-lymphocyte ratio (dNLR) as a prognostic marker in metastatic colorectal cancer (mCRC): RAXO substudy
|
Meklin, M.
|
|
|
36 |
S1 |
p. S18-S19
|
artikel
|
| 199 |
59P Development and validation of a simple scoring system to identify patients with poor outcomes from resection of colorectal liver metastases (CRLM) despite technical resectability
|
Chong, H.J.
|
|
|
36 |
S1 |
p. S32
|
artikel
|
| 200 |
89P Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer
|
Shen, J.P.Y-C.
|
|
|
36 |
S1 |
p. S44
|
artikel
|
| 201 |
295P Diabetes and its association with survival patterns in unresectable pancreatic adenocarcinoma: A North African cohort study
|
Takniouine, Y. Ait
|
|
|
36 |
S1 |
p. S116
|
artikel
|
| 202 |
244P Digital spatial profiling: Mapping tumor responses to radiotherapy in rectal cancer
|
Purcell, R.V.
|
|
|
36 |
S1 |
p. S96
|
artikel
|
| 203 |
102P Direct cost of healthcare analysis of signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: A UK private payer perspective
|
Mikropoulos, C.
|
|
|
36 |
S1 |
p. S49
|
artikel
|
| 204 |
88P Dissecting the transverse colon by embryologic origin: A monocentric retrospective study of midgut- and hindgut-derived tumors
|
Riccò, B.
|
|
|
36 |
S1 |
p. S44
|
artikel
|
| 205 |
437P Distinct tumor microenvironment composition of early onset gastric cancer peritoneal metastases
|
Sundar, R.
|
|
|
36 |
S1 |
p. S170
|
artikel
|
| 206 |
405P DKN-01 and atezolizumab as second or third-line therapy in advanced mismatch repair proficient (MMRp) oesophagogastric adenocarcinoma (OGA): WAKING trial
|
Gordon, A.
|
|
|
36 |
S1 |
p. S158-S159
|
artikel
|
| 207 |
173P Dose escalation STRATegy of regorafenib in Advanced HepatoCellular Carcinoma: Phase II STRATA-HCC trial
|
Fonseca, L.G.D.
|
|
|
36 |
S1 |
p. S72-S73
|
artikel
|
| 208 |
165P Early bevacizumab discontinuation (EBD) does not impact outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab (AB)
|
Carvalho, D.D.A.
|
|
|
36 |
S1 |
p. S71
|
artikel
|
| 209 |
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy
|
Taieb, J.
|
|
|
36 |
S1 |
p. S11-S12
|
artikel
|
| 210 |
85P Early-onset colorectal cancer: Linking clinical outcomes to socio-economic challenges across three tertiary cancer centres
|
Angelakas, A.
|
|
|
36 |
S1 |
p. S43
|
artikel
|
| 211 |
72P Early-onset colorectal cancer patients exhibits a distinct molecular fingerprint: Insights from a study of 1209 patients using NGS
|
Pretta, A.
|
|
|
36 |
S1 |
p. S39
|
artikel
|
| 212 |
323P Early safety and efficacy from the phase IIIb TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC)
|
Oh, D-Y.
|
|
|
36 |
S1 |
p. S126
|
artikel
|
| 213 |
428P Effectiveness of first-line regimen reintroduction in the second-line setting for advanced gastric cancer
|
Abdulaeva, R.S.
|
|
|
36 |
S1 |
p. S168
|
artikel
|
| 214 |
311P Effectiveness of tumor treating fields (TTFields) together with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC) preclinical models
|
Knop, J.
|
|
|
36 |
S1 |
p. S121
|
artikel
|
| 215 |
455P Effects of neighborhood deprivation index on survival in upper gastrointestinal cancers
|
Mukherjee, S.
|
|
|
36 |
S1 |
p. S175
|
artikel
|
| 216 |
37P Efficacy and safety of fruquintinib vs placebo by metastatic site in metastatic colorectal cancer: A FRESCO-2 subgroup analysis
|
Garcia-Carbonero, R.
|
|
|
36 |
S1 |
p. S22-S23
|
artikel
|
| 217 |
398P Efficacy and safety of radiation therapy alone in patients with stage II/III esophageal squamous cell carcinoma intolerant of chemotherapy and surgery: A multi-center retrospective study
|
Yoshii, T.
|
|
|
36 |
S1 |
p. S156
|
artikel
|
| 218 |
489P Efficacy of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced gastric cancer and metastatic colorectal cancer in clinical practice
|
Udagawa, S.
|
|
|
36 |
S1 |
p. S184
|
artikel
|
| 219 |
107P Efficacy of pembrolizumab and feasibility of organ preservation in non-metastatic, unresectable dMMR CRC
|
van den Dungen, L.
|
|
|
36 |
S1 |
p. S50
|
artikel
|
| 220 |
40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC
|
Stintzing, S.
|
|
|
36 |
S1 |
p. S25
|
artikel
|
| 221 |
91P Enumeration and immunophenotype of circulating tumor cells in colorectal cancer patients
|
Paz, A.
|
|
|
36 |
S1 |
p. S45
|
artikel
|
| 222 |
325P Epidemiological profile of biliary tract cancer (BTC) in Argentina: A real-world study by Latin American intergroup of gastrointestinal oncology (ILOGI)
|
Ituarte, A.C.
|
|
|
36 |
S1 |
p. S126-S127
|
artikel
|
| 223 |
314P Evaluating efficacy of Fc-enhanced CTLA-4 inhibitor botensilimab, bastilimab with or without CXCR4 inhibitor (BL-8040) in an orthotopic murine model
|
Lee, J.W.
|
|
|
36 |
S1 |
p. S122
|
artikel
|
| 224 |
440P Evaluation of recurrence patterns in patients treated with FLOT regimen
|
Lopes, D.D.
|
|
|
36 |
S1 |
p. S171-S172
|
artikel
|
| 225 |
118P Evaluation of the use of FOBT in colorectal cancer screening in the Republic of Kazakhstan from 2011 to 2024
|
Jumanov,
|
|
|
36 |
S1 |
p. S54
|
artikel
|
| 226 |
153P Evolution of second-line practices in the era of immunotherapy: Real-life data from the French prospective CHIEF cohort
|
Decraecker, M.
|
|
|
36 |
S1 |
p. S65-S66
|
artikel
|
| 227 |
331P Experience of durvalumab in unresectable advanced or metastatic biliary tract cancer: A multicenter study in Portugal
|
Marques, R. Fangueiro
|
|
|
36 |
S1 |
p. S129-S130
|
artikel
|
| 228 |
201P Exploring differentially expressed genes associated with HIF1A and tumor proliferation in hepatocellular carcinoma: Bioinformatics and in vivo study
|
Martínez-Geijo, J.
|
|
|
36 |
S1 |
p. S81
|
artikel
|
| 229 |
349P Exploring the landscape of DNA damage repair genes alterations in biliary tract cancer (BTC): A retrospective, single-center analysis
|
Valenzi, E.
|
|
|
36 |
S1 |
p. S137
|
artikel
|
| 230 |
488P Exploring the relationship between immunotherapy toxicity and treatment response in dMMR gastrointestinal malignancies
|
Freckelton, J.
|
|
|
36 |
S1 |
p. S184
|
artikel
|
| 231 |
496P Fertility preservation practices at gastrointestinal (GI) oncology in Europe: A Pan-European study
|
Ben-Aharon, I.
|
|
|
36 |
S1 |
p. S187
|
artikel
|
| 232 |
172P Final analysis of a randomized, double blind, phase II study of sorafenib with or without YIV-906 in patients with advanced HCC
|
Abou-Alfa, G.K.
|
|
|
36 |
S1 |
p. S72
|
artikel
|
| 233 |
329P First-line maintenance chemotherapy in patients with advanced pancreatic adenocarcinoma: A referral center monocentric cohort
|
Bartalini, L.
|
|
|
36 |
S1 |
p. S128
|
artikel
|
| 234 |
320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR)
|
Moehler, M.
|
|
|
36 |
S1 |
p. S124-S125
|
artikel
|
| 235 |
50P First-line treatment in MSI-H/dMMR metastatic colorectal cancer across Europe, Canada and the United States: A real-world survey of patients and clinicians
|
Seligmann, J.
|
|
|
36 |
S1 |
p. S29
|
artikel
|
| 236 |
274P 5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
|
Trovato, G.
|
|
|
36 |
S1 |
p. S108
|
artikel
|
| 237 |
444P Gastric cancer: Artificial intelligence, synergetics, complex system analysis, biometrics and modeling of alive supersystems for best management
|
Kshivets, O.
|
|
|
36 |
S1 |
p. S172
|
artikel
|
| 238 |
212P Gastrointestinal neuroendocrine tumors in early onset patient: A retrospective study in an ENETS excellence centre
|
Baldini, L.
|
|
|
36 |
S1 |
p. S86
|
artikel
|
| 239 |
179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis
|
Salani, F.
|
|
|
36 |
S1 |
p. S75-S76
|
artikel
|
| 240 |
454P Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma
|
Lordick, F.
|
|
|
36 |
S1 |
p. S174
|
artikel
|
| 241 |
312P GPCR1 as a selective target in pancreatic cancer: Preclinical efficacy and safety of first-in-class SKM104-MA-L2, a topoisomerase-based antibody-drug conjugate with high therapeutic index
|
Merabet, M.K.
|
|
|
36 |
S1 |
p. S121-S122
|
artikel
|
| 242 |
57P Hepatic arterial infusion with mitomycin C in patients with colorectal liver metastases
|
Vandewinckele, J.
|
|
|
36 |
S1 |
p. S31-S32
|
artikel
|
| 243 |
436P Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions
|
Feng, Y.
|
|
|
36 |
S1 |
p. S170
|
artikel
|
| 244 |
363P HER-2 neu expression in gallbladder cancer: A real-world study on molecular alterations and targeted therapy response
|
Singhal, R.
|
|
|
36 |
S1 |
p. S142
|
artikel
|
| 245 |
431P High amphiregulin (AREG) plasma levels are associated with shorter survival in patients with advanced gastric cancer but are not predictive for response to cetuximab in combination with first-line chemotherapy in the global EXPAND phase III trial
|
Kobitzsch, B.
|
|
|
36 |
S1 |
p. S169
|
artikel
|
| 246 |
354P High serum ferritin level is prognostic for progression-free and overall survival as a potential biomarker in patients with advanced biliary tract cancer
|
Akkus, E.
|
|
|
36 |
S1 |
p. S139
|
artikel
|
| 247 |
188P Histomorphologic features characterising response to neoadjuvant immune checkpoint inhibitor therapy in hepatocellular carcinoma
|
Torkpour, A.
|
|
|
36 |
S1 |
p. S78
|
artikel
|
| 248 |
443P HSF2 upregulates viral oncogenes by altering the epigenetic landscape at key viral promoter in EBVaGC
|
Cutrone, L.
|
|
|
36 |
S1 |
p. S172
|
artikel
|
| 249 |
503P Identifying clinical development opportunities for antibody drug conjugates (ADCs) in gastrointestinal (GI) cancers through RNA-expression analysis in 637 cell lines
|
Freckelton, J.
|
|
|
36 |
S1 |
p. S189
|
artikel
|
| 250 |
350P IDH2-mutated cholangiocarcinoma: A case series highlighting challenges and insights
|
Al Mahmasani, L.
|
|
|
36 |
S1 |
p. S137
|
artikel
|
| 251 |
407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial
|
Masetti, M.
|
|
|
36 |
S1 |
p. S159
|
artikel
|
| 252 |
97P Immune profiling enhances stratification in stage II colon cancer (CC): A novel approach integrating consensus molecular subtype (CMS) classification and immune cell (IC) infiltration
|
Vivas, C. Santos
|
|
|
36 |
S1 |
p. S47
|
artikel
|
| 253 |
332P Impact of chemoimmunotherapy (CIO) vs chemotherapy (CT) alone in patients with HRD-positive and HRD-negative biliary tract cancers (BTC): A multicenter retrospective survival analysis
|
Abidoye, O.
|
|
|
36 |
S1 |
p. S130
|
artikel
|
| 254 |
500P Impact of chemotherapy-induced peripheral neuropathy in quality of life of patients treated with oxaliplatin: A prospective real-world study
|
Couto, M.C.
|
|
|
36 |
S1 |
p. S188
|
artikel
|
| 255 |
420P Impact of early tumor shrinkage as a prognostic predictor in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan
|
Inamoto, R.
|
|
|
36 |
S1 |
p. S165
|
artikel
|
| 256 |
402P Impact of larger tumor lengths on survival in esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: Real-World outcomes
|
Batham, S.
|
|
|
36 |
S1 |
p. S157
|
artikel
|
| 257 |
304P Impact of neoadjuvant and adjuvant strategies on outcomes in non-metastatic pancreatic cancer
|
Blanchet-Deverly, S.
|
|
|
36 |
S1 |
p. S119
|
artikel
|
| 258 |
48P Impact of the KRAS mutation subtype on treatment response in metastatic colorectal cancer
|
Masri, N.
|
|
|
36 |
S1 |
p. S28-S29
|
artikel
|
| 259 |
290P Impact of the systemic inflammation index (SIRI) and artificial intelligence(AI)-based muscle mass (FocusedON® software) on chemotherapy toxicity and prognosis in metastatic pancreatic cancer: A proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group
|
Pacheco-Barcia, V.E.
|
|
|
36 |
S1 |
p. S114
|
artikel
|
| 260 |
116P Improving colorectal cancer detection with AI-assisted colonoscopy: A systematic review and meta-analysis of 38 RCTs with GRADE assessment
|
Qutob, I.A.
|
|
|
36 |
S1 |
p. S53-S54
|
artikel
|
| 261 |
164P Increase in LAG3-positive CD8+ T-cell after atezolizumab plus bevacizumab therapy as a predictor of progression-free survival in unresectable hepatocellular carcinoma
|
Yamada, T.
|
|
|
36 |
S1 |
p. S71
|
artikel
|
| 262 |
239P Institutional prospective database of short-course radiotherapy (SCRT) by intensity modulated radiotherapy (IMRT) in rectal cancer: Toxicity and quality of life (QOL) outcomes
|
Basu, T.
|
|
|
36 |
S1 |
p. S95
|
artikel
|
| 263 |
94P Integrating circulating biomarkers, TLRs/VDRs polymorphisms and microbial translocation for prognosis in stage III colorectal cancer
|
Koulouridi, A.
|
|
|
36 |
S1 |
p. S46
|
artikel
|
| 264 |
13P Integrating tissue (TBx) and liquid biopsy (LBx) comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer (mCRC): Findings from the CAPRI-2 GOIM study
|
Cioli, E.
|
|
|
36 |
S1 |
p. S10
|
artikel
|
| 265 |
96P Integrative risk stratification in stage II-III colorectal cancer: Associations between molecular alterations, microbial translocation, and TLR polymorphisms
|
Koulouris, A.V.
|
|
|
36 |
S1 |
p. S47
|
artikel
|
| 266 |
338P Interim report of the real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer patients in Japan with FGFR2 fusion or FGFR2 rearrangement (JON2303 B)
|
Kimura, Y.
|
|
|
36 |
S1 |
p. S132-S133
|
artikel
|
| 267 |
82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer
|
Mauri, G.
|
|
|
36 |
S1 |
p. S42
|
artikel
|
| 268 |
202P Investigating molecular pathways of acquired resistance to lenvatinib in hepatocellular carcinoma: From cellular models to patient-derived samples
|
Amato, L.
|
|
|
36 |
S1 |
p. S82
|
artikel
|
| 269 |
197P In vivo bioluminescence imaging to study NF-κB-related tumor progression in primary liver cancer
|
Schmid, M.T.
|
|
|
36 |
S1 |
p. S80
|
artikel
|
| 270 |
337P Ivosidenib for IDH1-mutant intrahepatic cholangiocarcinoma: Insights from a multicenter real-world study
|
Gardini, A. Casadei
|
|
|
36 |
S1 |
p. S132
|
artikel
|
| 271 |
322P Ivosidenib in pretreated Japanese (JPN) patients (pts) with mutant isocitrate dehydrogenase 1 (mIDH1) nonresectable/metastatic cholangiocarcinoma (n/mCCA): Phase II study results
|
Satake, T.
|
|
|
36 |
S1 |
p. S125
|
artikel
|
| 272 |
210P KINETICS: Real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67)
|
Vandamme, T.
|
|
|
36 |
S1 |
p. S85
|
artikel
|
| 273 |
281P KRAS genomic landscape and outcomes in pancreatic adenocarcinoma: A single-institution experience
|
Montero de la Fuente, L.
|
|
|
36 |
S1 |
p. S110-S111
|
artikel
|
| 274 |
283P KRAS mutations as prognostic and predictive factor in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A single-center study
|
Di Francesco, L.
|
|
|
36 |
S1 |
p. S111
|
artikel
|
| 275 |
175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
|
Lombardi, P.
|
|
|
36 |
S1 |
p. S73-S74
|
artikel
|
| 276 |
120P Linking Lynch syndrome gene mutations to the gut microbiome profile: A predictive approach for colorectal cancer risk
|
Half, E.E.
|
|
|
36 |
S1 |
p. S55
|
artikel
|
| 277 |
347P Liquid biopsy for longitudinal molecular characterization of patients (pts) with biliary tract cancer (BTC)
|
Tesini, G.
|
|
|
36 |
S1 |
p. S136
|
artikel
|
| 278 |
252P Local and symptomatic control evaluation in palliative radiotherapy for rectal adenocarcinoma in frail, elderly, or metastatic patients
|
Bisson, E.
|
|
|
36 |
S1 |
p. S99
|
artikel
|
| 279 |
292P Long survival in metastatic pancreatic cancer: Clinical and biological predictors from a large retrospective cohort
|
Tarabay, A.
|
|
|
36 |
S1 |
p. S115
|
artikel
|
| 280 |
230P Long-term follow-up of a nationwide cohort of patients with locally advanced rectal cancer treated with total neoadjuvant treatment according to the LARCT-US schedule and risk factors for recurrence
|
Imam, I.
|
|
|
36 |
S1 |
p. S92
|
artikel
|
| 281 |
441P Long-term quality of life after distal and pylorus-preserving gastrectomy for stage I gastric cancer: A prospective multi-institutional study (CCOG1601)
|
Tanaka, C.
|
|
|
36 |
S1 |
p. S172
|
artikel
|
| 282 |
246P Machine learning-based prediction of recurrence after curative treatment for rectal cancer: A multi-model analysis from a tertiary cancer centre
|
Tantravahi, U.
|
|
|
36 |
S1 |
p. S97
|
artikel
|
| 283 |
71P Management of adolescents and young adults (AYA) metastatic colorectal cancer (mCRC) patients (pts): A single institution analysis
|
Spring, A.
|
|
|
36 |
S1 |
p. S38-S39
|
artikel
|
| 284 |
151P Matching-adjusted indirect comparisons (MAICs) of nivolumab + ipilimumab (N + I) vs durvalumab + tremelimumab (D + T) and atezolizumab + bevacizumab (A + B) for first-line (1L) unresectable hepatocellular carcinoma (uHCC)
|
Kudo, M.
|
|
|
36 |
S1 |
p. S64
|
artikel
|
| 285 |
126P MetaCoLon project: The interaction between nuclear related factor-2 (Nrf2) signaling pathway and Pyruvate Kinase Isozyme M2 (PKM2) metabolic pathway in colon cancer
|
Manolakou, S.D.
|
|
|
36 |
S1 |
p. S56
|
artikel
|
| 286 |
432P Metastasic patterns and inflamatory biomarkers: Predicting outcomes in gastric cancer
|
Rubio, D.A.
|
|
|
36 |
S1 |
p. S169
|
artikel
|
| 287 |
272P Metastatic pancreatic adenocarcinoma: Real-world efficacy of first-line treatment
|
Debiais, M.
|
|
|
36 |
S1 |
p. S107
|
artikel
|
| 288 |
53P Microsatellite-instability-high/mismatch-repair-deficient (MSI-H/dMMR) and BRAFV600E mutant (BRAFm) advanced colorectal cancers (CRC) treated with immune checkpoint inhibitors (ICI): Real-world data from the Royal Marsden Hospital
|
Le, H.M.L.
|
|
|
36 |
S1 |
p. S30
|
artikel
|
| 289 |
79P miR-195 and miR-549a as potential biomarkers for early-onset colorectal cancer
|
Coronel, J.
|
|
|
36 |
S1 |
p. S41
|
artikel
|
| 290 |
29P Mismatch repair a biomarker of prognosis and overall survival of Latin American with colorectal metastatic patients
|
Zambrano, L. Rivero
|
|
|
36 |
S1 |
p. S17
|
artikel
|
| 291 |
413P Mismatch repair deficiency (MMRd) in esophagogastric adenocarcinoma (ADC) following chemotherapy for resectable disease: Correlation with survival and recurrence patterns from ST03 and OE05 trials
|
Ntellas, P.
|
|
|
36 |
S1 |
p. S162
|
artikel
|
| 292 |
411P Molecular characterization of esophagogastric adenocarcinoma: Prognostic and predictive impact of MSI and MSS tumors
|
Catoya-Villa, J.L.
|
|
|
36 |
S1 |
p. S161
|
artikel
|
| 293 |
284P Molecular landscape of advanced pancreatic cancer: Results from NGS testing in real-world clinical practice
|
Godall, M. Busquets
|
|
|
36 |
S1 |
p. S111-S112
|
artikel
|
| 294 |
348P Molecular profiling success in advanced cholangiocarcinoma (CCA) based on tumour acquisition method
|
Vrana, E.
|
|
|
36 |
S1 |
p. S136
|
artikel
|
| 295 |
152P MORPHEUS-Liver: A phase Ib/II, randomised study evaluating tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients (pts) with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
|
Finn, R.S.
|
|
|
36 |
S1 |
p. S65
|
artikel
|
| 296 |
404P MRD analysis following curative intent treatment in patients with locally advanced esophageal cancer utilizing MAESTRO, an ultrasensitive ctDNA assay
|
Patel, A.K.
|
|
|
36 |
S1 |
p. S158
|
artikel
|
| 297 |
360P MTAP loss in pancreatobiliary cancers: Insights into co-occurring genetic alterations
|
Diaz, W.E. Cruz
|
|
|
36 |
S1 |
p. S141
|
artikel
|
| 298 |
193P Multidisciplinary teams (MDTs) for hepatocellular carcinoma (HCC): Maturity and optimal practices in Europe and Canada (EUCAN)
|
Vogel, A.
|
|
|
36 |
S1 |
p. S79-S80
|
artikel
|
| 299 |
456P Mutational signature dynamics in gastric and esophageal cancers: A retrospective comprehensive genomic analysis
|
Khan, N.B.
|
|
|
36 |
S1 |
p. S175
|
artikel
|
| 300 |
11P NALIRIFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer: A phase I study
|
Zhou, H.
|
|
|
36 |
S1 |
p. S9
|
artikel
|
| 301 |
293P NALLONG: Real-world evidence study and prognosis factors on long-term survivors of metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan: Hypothesis-driven subgroups analysis
|
Ueno, M.
|
|
|
36 |
S1 |
p. S115-S116
|
artikel
|
| 302 |
214P National insights into epidemiological trends and outcomes of malignant neoplasms of the small intestine: A big data analysis
|
Kim, J-O.
|
|
|
36 |
S1 |
p. S86-S87
|
artikel
|
| 303 |
334P Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine and durvalumab: A large real-life worldwide population
|
Lo Prinzi, F.
|
|
|
36 |
S1 |
p. S131
|
artikel
|
| 304 |
401P Neoadjuvant chemo-radiotherapy in older patients with oesophageal cancer
|
Aquilano, M.
|
|
|
36 |
S1 |
p. S157
|
artikel
|
| 305 |
452P Neoadjuvant chemotherapy in gastric adenocarcinoma: Challenges to overcome in Latin American population
|
Ruiz, G. Calderillo
|
|
|
36 |
S1 |
p. S173
|
artikel
|
| 306 |
111P Neoadjuvant high-dose vitamin C (HDVC) combined with ipilimumab and nivolumab in proficient mismatch repair (pMMR) colon cancer (CC): First safety analysis of ALFEO pilot study
|
Amatu, A.
|
|
|
36 |
S1 |
p. S51-S52
|
artikel
|
| 307 |
109P Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer: The west of Scotland experience
|
Ramchander, N.C.
|
|
|
36 |
S1 |
p. S50-S51
|
artikel
|
| 308 |
187P Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L.
|
|
|
36 |
S1 |
p. S78
|
artikel
|
| 309 |
106P Neoadjuvant immunotherapy with prolgolimab in locally advanced dMMR/MSI colorectal cancer: Final pathological response analysis and 12-months disease-free survival
|
Kuznetsova, O.A.
|
|
|
36 |
S1 |
p. S50
|
artikel
|
| 310 |
303P Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis
|
Rota, S.
|
|
|
36 |
S1 |
p. S119
|
artikel
|
| 311 |
157P Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses
|
Qin, S.
|
|
|
36 |
S1 |
p. S67
|
artikel
|
| 312 |
60P No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC)
|
Osterlund, E.
|
|
|
36 |
S1 |
p. S33
|
artikel
|
| 313 |
125P Novel CBM signalosome inhibitor revealed the essentiality of CBM signalosome for KRAS mutant colorectal cancer
|
Wang, F.
|
|
|
36 |
S1 |
p. S56
|
artikel
|
| 314 |
54P Oligoprogression under immune checkpoint inhibitors (ICI) for metastatic colorectal cancer with microsatellite instability: A distinct entity requiring tailored management
|
Grosnon, C.
|
|
|
36 |
S1 |
p. S30-S31
|
artikel
|
| 315 |
231P Oncological outcomes in rectal adenocarcinoma patients failing to respond to total neoadjuvant therapy
|
Mitry, E.
|
|
|
36 |
S1 |
p. S92
|
artikel
|
| 316 |
495P Optimising chemotherapy tolerability in older gastrointestinal cancer patients with initial dose reduction
|
Chan, W.W.L.
|
|
|
36 |
S1 |
p. S186
|
artikel
|
| 317 |
296P Optimizing progression-free survival prediction in locally advanced and metastatic pancreatic adenocarcinoma using a regimen-specific nomogram: Insights from Morocco
|
Tafenzi, H.A.
|
|
|
36 |
S1 |
p. S116-S117
|
artikel
|
| 318 |
12P ORGANOTREAT-01: A pioneer phase I/II multicenter trial of organoid-driven precision medicine for refractory colorectal cancer
|
Jaulin, F.
|
|
|
36 |
S1 |
p. S9-S10
|
artikel
|
| 319 |
51P Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: A cohort study
|
Mas, L.
|
|
|
36 |
S1 |
p. S29-S30
|
artikel
|
| 320 |
235P Outcomes of a rectal cancer population treated with capecitabine-based chemoradiation compared with a cohort switched to S-1 for cardiotoxicity
|
Osterlund, P.J.
|
|
|
36 |
S1 |
p. S94
|
artikel
|
| 321 |
156P Outcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA trial eligibility: Results of the international DT-real study
|
Celsa, C.
|
|
|
36 |
S1 |
p. S66-S67
|
artikel
|
| 322 |
485P Ovarian metastasis from gastrointestinal cancers: Clinicopathologic features, molecular profile, and outcomes, a single centre review in Oman
|
Al Ghoche, A.A.
|
|
|
36 |
S1 |
p. S183
|
artikel
|
| 323 |
318P Overexpression of SNHG10 lncRNA promotes pancreatic cancer growth through miRNA-150-5p/VEGFA/EGFR/AKT signaling
|
Pandya, G.
|
|
|
36 |
S1 |
p. S123
|
artikel
|
| 324 |
316P Pancreatic cancer cells are sensitized to FOLFIRINOX treatment by co-application with tumor treating fields (TTFields)
|
Ene, H.
|
|
|
36 |
S1 |
p. S123
|
artikel
|
| 325 |
423P Pathological complete response rates with perioperative FLOT chemotherapy in gastric and gastroesophageal junction adenocarcinoma: A retrospective analysis from Eastern India
|
Rastogi, I.
|
|
|
36 |
S1 |
p. S166
|
artikel
|
| 326 |
344P Patient characteristics, molecular testing, and treatment patterns of patients with cholangiocarcinoma in the United States: Focus on mIDH1 patients
|
Rimassa, L.
|
|
|
36 |
S1 |
p. S135
|
artikel
|
| 327 |
502P Patient-derived organoid models reveal variant-specific responses and synergistic drug effects in KRAS-driven digestive cancers
|
Ronteix, G.
|
|
|
36 |
S1 |
p. S188-S189
|
artikel
|
| 328 |
68P Patients’ treatment experiences and involvement in treatment decision-making in metastatic colorectal cancer: Results of a patient survey in Europe and Canada
|
Saunders, M.P.
|
|
|
36 |
S1 |
p. S37
|
artikel
|
| 329 |
52P Pembrolizumab real-world data, including inflammatory indices in dMMR/MSI-H mCRC from a tertiary cancer centre
|
Christodoulis, E.
|
|
|
36 |
S1 |
p. S30
|
artikel
|
| 330 |
306P Perioperative and oncological outcomes of laparoscopic versus open pancreaticoduodenectomy: A meta-analysis of randomized controlled trials
|
Abdelghany, A.
|
|
|
36 |
S1 |
p. S120
|
artikel
|
| 331 |
9P Phase I dose-escalation study of GCC19CART: A novel CAR T cell therapy for metastatic colorectal cancer in the United States
|
Schlechter, B.L.
|
|
|
36 |
S1 |
p. S8
|
artikel
|
| 332 |
110P Phase II trial of low dose neoadjuvant immunotherapy in locally advanced MSI/dMMR colorectal cancer: First safety and efficacy outcomes
|
Zagidullina, A.A.
|
|
|
36 |
S1 |
p. S51
|
artikel
|
| 333 |
10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC)
|
Yamaguchi, K.
|
|
|
36 |
S1 |
p. S8-S9
|
artikel
|
| 334 |
67P Physicians’ preferences for later-line treatment of metastatic colorectal cancer in Germany and the UK
|
Geiger, A.
|
|
|
36 |
S1 |
p. S36-S37
|
artikel
|
| 335 |
20P Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18)
|
Inagaki, C.
|
|
|
36 |
S1 |
p. S14
|
artikel
|
| 336 |
63P Pooled safety analysis of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC) using individual patient data (IPD) from five clinical trials
|
Yamazaki, K.
|
|
|
36 |
S1 |
p. S34-S35
|
artikel
|
| 337 |
24P Precision medicine in colorectal cancer: Personalizing treatment for improved outcomes?
|
Soueidy, C.
|
|
|
36 |
S1 |
p. S15-S16
|
artikel
|
| 338 |
117P Predictors of significant lesions in colon capsule endoscopy
|
Hansen, L.Ø.
|
|
|
36 |
S1 |
p. S54
|
artikel
|
| 339 |
494P Preliminary data from the TEOGIC study: A comprehensive characterization of early-onset gastrointestinal cancer in Spain
|
Huerta-Hernández, A.E.
|
|
|
36 |
S1 |
p. S186
|
artikel
|
| 340 |
340P Preliminary report on advanced biliary cancer receiving multimodality treatment in the immunotherapy era: A real-world multicenter experience
|
Passardi, A.
|
|
|
36 |
S1 |
p. S133
|
artikel
|
| 341 |
486P Preliminary results from a first-in-human phase I study of a dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, BA3182, in pts with treatment refractory metastatic adenocarcinoma
|
Starodub, A.
|
|
|
36 |
S1 |
p. S183-S184
|
artikel
|
| 342 |
484P Pressurized intraperitoneal aerosol chemotherapy for peritoneal metastases: Insights from a Portuguese center
|
Oura, M.J.
|
|
|
36 |
S1 |
p. S183
|
artikel
|
| 343 |
294P Prevalence and prognostic value of claudin 18.2 expression in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma in Germany
|
Wild, P.J.
|
|
|
36 |
S1 |
p. S116
|
artikel
|
| 344 |
498P Prevalence of malnutrition and its impact on hospitalized gastrointestinal cancer patients: Screening results conducted at admission to the oncology inpatient unit
|
Pereira, M.M.
|
|
|
36 |
S1 |
p. S187
|
artikel
|
| 345 |
86P Prevalence of PIK3CA and PTEN alterations from upfront genomic testing of newly diagnosed colorectal cancer (CRC): A population-based series
|
Kerrin, L.A.
|
|
|
36 |
S1 |
p. S43-S44
|
artikel
|
| 346 |
409P Prognostic factors associated with survival for patients with HER2+ GEA
|
Bridgewater, J.A.
|
|
|
36 |
S1 |
p. S160
|
artikel
|
| 347 |
247P Prognostic impact of microsatellite instability and survival disparities in rectal cancer: A SEER-based retrospective analysis
|
Arunachalam, J.
|
|
|
36 |
S1 |
p. S97
|
artikel
|
| 348 |
23P Prognostic impact of secondary actionable alterations in dMMR/MSI-H digestive tumors
|
Lago, N. Martinez
|
|
|
36 |
S1 |
p. S15
|
artikel
|
| 349 |
421P Prognostic impact of the modified Glasgow prognostic score in advanced gastric and gastroesophageal junction cancer treated with first-line nivolumab plus chemotherapy: A multi-center retrospective study
|
Ogura, N.
|
|
|
36 |
S1 |
p. S165
|
artikel
|
| 350 |
69P Prognostic impact of weight loss on overall survival in metastatic colorectal cancer: A call for integrating nutritional interventions into oncological care
|
Alcaraz, A.
|
|
|
36 |
S1 |
p. S37-S38
|
artikel
|
| 351 |
70P Prognostic implications of bone metastasis in early-onset colorectal cancer
|
Vadehra, D.
|
|
|
36 |
S1 |
p. S38
|
artikel
|
| 352 |
353P Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab
|
Camera, S.
|
|
|
36 |
S1 |
p. S139
|
artikel
|
| 353 |
190P Prognostic scoring system for hepatocellular carcinoma: Risk stratification and survival prediction in a Thai cohort
|
Neesanun, S.
|
|
|
36 |
S1 |
p. S79
|
artikel
|
| 354 |
429P Prognostic significance of HER2-low status in advanced gastric cancer
|
Karaoglan, B.B.
|
|
|
36 |
S1 |
p. S168
|
artikel
|
| 355 |
289P Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: Results from the PANTHEIA–SEOM study
|
Ponce, C. Guillen
|
|
|
36 |
S1 |
p. S113-S114
|
artikel
|
| 356 |
288P Prognostic value and clinical implication of ctDNA profiling in metastatic pancreatic ductal adenocarcinoma patients: A multicenter European study
|
Candia, L.
|
|
|
36 |
S1 |
p. S113
|
artikel
|
| 357 |
64P PROMETCO: Real-world characteristics and safety outcomes of patients with metastatic colorectal cancer (mCRC) after two disease progressions, including patients with ECOG-PS >2
|
Garcia-Carbonero, R.
|
|
|
36 |
S1 |
p. S35
|
artikel
|
| 358 |
270P Propensity score matched analysis of inoperable pancreatic cancer treated with ablative stereotactic MR-guided radiotherapy with or without subsequent surgery
|
Herrera, R.A.
|
|
|
36 |
S1 |
p. S106
|
artikel
|
| 359 |
73P Proteome analysis of patients with colorectal cancer in Ireland
|
O'Reilly, M.O.
|
|
|
36 |
S1 |
p. S39
|
artikel
|
| 360 |
267P Provisional results of immunotherapy combined with LSTA1 plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma
|
Dean, A.
|
|
|
36 |
S1 |
p. S105-S106
|
artikel
|
| 361 |
497P Psychological distress in caregivers of gastrointestinal cancers patients: A study of PTSD, anxiety, and depression
|
Qutob, I.A.
|
|
|
36 |
S1 |
p. S187
|
artikel
|
| 362 |
114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging
|
Randon, G.
|
|
|
36 |
S1 |
p. S53
|
artikel
|
| 363 |
229P Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer: Clinical and quality of life analysis (NCT03997435)
|
Lai, C.K.Y.
|
|
|
36 |
S1 |
p. S91
|
artikel
|
| 364 |
395P RATIONALE-306 subgroup analysis of patients (pts) with advanced/metastatic esophageal squamous cell cancer (ESCC) and tumor area positivity (TAP) score ≥5%
|
Tougeron, D.
|
|
|
36 |
S1 |
p. S154-S155
|
artikel
|
| 365 |
394P Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: A pooled analysis of two phase III trials
|
Luo, H.Y.
|
|
|
36 |
S1 |
p. S154
|
artikel
|
| 366 |
45P Real life comparison of toxicity from cetuximab and panitumumab in the first-line treatment of metastatic colorectal cancer
|
Polwart, C.
|
|
|
36 |
S1 |
p. S27-S28
|
artikel
|
| 367 |
406P Real-life use of docetaxel, cisplatin and 5-FU (DCFm) combined with nivolumab in advanced gastroesophageal cancers: The TRINIGAST observational study
|
Bauer, A.
|
|
|
36 |
S1 |
p. S159
|
artikel
|
| 368 |
66P Real-world data from fruquintinib in later line metastatic colorectal cancer
|
Verdasca, F.R.
|
|
|
36 |
S1 |
p. S36
|
artikel
|
| 369 |
400P Real-world data of different neoadjuvant chemoradiotherapy regimens in locally advanced esophageal cancer
|
Jurado, L. Casas
|
|
|
36 |
S1 |
p. S157
|
artikel
|
| 370 |
333P Real-world efficacy and toxicity data of durvalumab plus chemotherapy compared with chemotherapy in patients with advanced biliary tract cancer: A retrospective cohort at the National Cancer Institute in Mexico
|
Nube, L. Lagarde
|
|
|
36 |
S1 |
p. S130
|
artikel
|
| 371 |
271P Real-world evidence analysis of NALIRIFOX in metastatic pancreatic ductal adenocarcinoma
|
Friedrich, A.
|
|
|
36 |
S1 |
p. S106-S107
|
artikel
|
| 372 |
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort
|
Lavingia, V.
|
|
|
36 |
S1 |
p. S45
|
artikel
|
| 373 |
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia
|
Alshammari, K.
|
|
|
36 |
S1 |
p. S127
|
artikel
|
| 374 |
168P Real-world experience of immune checkpoint inhibitors in Hepatocellular carcinoma from India: Efficacy and liver related toxicity
|
Udupa M S, N.
|
|
|
36 |
S1 |
p. S71
|
artikel
|
| 375 |
46P Real-world first-line treatment outcomes of patients with KRAS G12C- or non- G12C KRAS mutated metastatic colorectal cancer in the US
|
Eng, C.
|
|
|
36 |
S1 |
p. S28
|
artikel
|
| 376 |
21P Real-world genomic profiles in patients with HER2-positive metastatic colorectal cancer
|
Matsubara, Y.
|
|
|
36 |
S1 |
p. S14
|
artikel
|
| 377 |
161P Real-world outcomes for unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab plus bevacizumab (A+B) in the United States (US)
|
Pinato, D.J.
|
|
|
36 |
S1 |
p. S69
|
artikel
|
| 378 |
305P Real-world outcomes in borderline resectable pancreatic cancer: A retrospective cohort from a multidisciplinary center in Argentina
|
Basbus, L.
|
|
|
36 |
S1 |
p. S120
|
artikel
|
| 379 |
42P Real-world outcomes of anti-EGFR rechallenge in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
|
Baselga, P. Mascaró
|
|
|
36 |
S1 |
p. S26
|
artikel
|
| 380 |
418P Real-world outcomes of first-line nivolumab for advanced gastric or gastroesophageal junction adenocarcinoma: A multicenter, retrospective, observational study
|
Qiu, H.
|
|
|
36 |
S1 |
p. S164
|
artikel
|
| 381 |
182P Real-world outcomes of transarterial chemoembolization (TACE) in hepatocellular carcinoma: A 10-year retrospective study from a Swiss tertiary cancer center
|
Pesola, G.
|
|
|
36 |
S1 |
p. S76
|
artikel
|
| 382 |
453P Real-world (RW) evidence in gastric and esophageal cancer: First results of patients (pts) treated with nivolumab (NIVO) plus chemotherapy (chemo) from the noninterventional INGA study in Germany
|
Stein, A.
|
|
|
36 |
S1 |
p. S174
|
artikel
|
| 383 |
419P Real-world treatment pattern and biomarker testing landscape of advanced gastric/gastroesophageal junction cancer (GC/GEJC) in China (SURPASS study)
|
Liu, R.
|
|
|
36 |
S1 |
p. S164-S165
|
artikel
|
| 384 |
425P Real-world treatment patterns and outcomes in patients with advanced gastric cancer in Japan
|
Kawakami, H.
|
|
|
36 |
S1 |
p. S166-S167
|
artikel
|
| 385 |
330P Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)
|
Gardini, A. Casadei
|
|
|
36 |
S1 |
p. S129
|
artikel
|
| 386 |
38P Real-world use of encorafenib + cetuximab (EC) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC): A pooled analysis of European observational studies
|
Cremolini, C.
|
|
|
36 |
S1 |
p. S23-S24
|
artikel
|
| 387 |
189P Reappraisal of alpha-fetoprotein (AFP) for early relapse detection after hepatocellular carcinoma (HCC) resection or transplantation
|
Patelli, G.
|
|
|
36 |
S1 |
p. S78
|
artikel
|
| 388 |
44P Rechallenge with anti-HER2 regimens in metastatic colorectal cancer: The retrospective RHEA study
|
Bianchi, A. Sartore
|
|
|
36 |
S1 |
p. S27
|
artikel
|
| 389 |
25P Reflex molecular biomarker testing in colorectal cancer: Pathway insights from the South-East England network
|
Liu, W.K.
|
|
|
36 |
S1 |
p. S16
|
artikel
|
| 390 |
34P Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity
|
Da Silva, I. Martín
|
|
|
36 |
S1 |
p. S20
|
artikel
|
| 391 |
321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC)
|
Roderburg, C.
|
|
|
36 |
S1 |
p. S125
|
artikel
|
| 392 |
119P Results of colorectal cancer screening in the Republic of Kazakhstan over 14 years (2011-2024)
|
Jumanov, A.
|
|
|
36 |
S1 |
p. S54-S55
|
artikel
|
| 393 |
211P Retrospective analysis of liver transplantation eligibility based on the Milan criteria in patients with gastroenteropancreatic neuroendocrine tumors
|
Verhé, M.
|
|
|
36 |
S1 |
p. S85
|
artikel
|
| 394 |
346P Revealing biomarkers of response to chemo-immunotherapy in biliary tract cancer
|
Balsano, R.
|
|
|
36 |
S1 |
p. S135
|
artikel
|
| 395 |
362P Role of limited NGS in gallbladder cancer in LMIC: A real-world data of genomic profile and survival outcomes
|
Singhal, R.
|
|
|
36 |
S1 |
p. S141
|
artikel
|
| 396 |
483P Safety and efficacy of cisplatin and nab-paclitaxel pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase IB study
|
Kössler, T.
|
|
|
36 |
S1 |
p. S182
|
artikel
|
| 397 |
427P Safety and efficacy of nivolumab plus chemotherapy in patients with advanced gastric cancer with ascites: A multi-center retrospective study in Japan
|
Onishi, M.
|
|
|
36 |
S1 |
p. S167-S168
|
artikel
|
| 398 |
186P Safety and response to neoadjuvant lenvatinib for poor-prognosis BCLC A hepatocellular carcinoma treated by percutaneous ablation in a curative intent: Preliminary analysis of the French LENVABLA multicentre phase II trial (NCT05113186)
|
Nahon, P.
|
|
|
36 |
S1 |
p. S77
|
artikel
|
| 399 |
113P Safety of adjuvant S-1 after capecitabine-induced toxicity in patients with colon cancer: A population-based real-world study
|
Ghedri, A.
|
|
|
36 |
S1 |
p. S52-S53
|
artikel
|
| 400 |
275P Second-line nanoliposomal irinotecan plus fluorouracil (NIF) versus fluoropyrimidine-based chemotherapy plus oxaliplatin (OF) after gemcitabine plus nab-paclitaxel in patients with advanced pancreatic cancer patients: Efficacy comparison using real-world data evidence
|
Pascual, J. Rodriguez
|
|
|
36 |
S1 |
p. S108
|
artikel
|
| 401 |
47P Sequence analysis of three different treatment alternatives for patients with left-side RAS wild type metastatic colorectal cancer in Spain
|
García-Paredes, B.
|
|
|
36 |
S1 |
p. S28
|
artikel
|
| 402 |
276P Sequential chemotherapy with gemcitabine and paclitaxel after FOLFIRINOX failure in metastatic pancreatic adenocarcinoma: A retrospective monocentric study
|
Lafitte, E.
|
|
|
36 |
S1 |
p. S108
|
artikel
|
| 403 |
224P Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01)
|
Tian, F.
|
|
|
36 |
S1 |
p. S90
|
artikel
|
| 404 |
238P Short-course radiotherapy for older patients with locally advanced rectal cancer and unfit for chemotherapy: The SOFT study
|
Rosati, G.
|
|
|
36 |
S1 |
p. S94-S95
|
artikel
|
| 405 |
457P Size of the largest nonmetastatic regional lymph node: A validated prognostic marker in patients with esophageal, junctional or gastric adenocarcinoma
|
Kloft, M.
|
|
|
36 |
S1 |
p. S175-S176
|
artikel
|
| 406 |
451P Socioeconomic and clinical determinants of quality of life in Moroccan gastric cancer patients
|
Kriouile, S.
|
|
|
36 |
S1 |
p. S173
|
artikel
|
| 407 |
448P Spatial and quantitative expression of Toll-like receptors (TLRs) 4, 5 and 9 in gastric premalignant lesions in presence and absence of Helicobacter pylori
|
Villarroel-Espindola, F.
|
|
|
36 |
S1 |
p. S173
|
artikel
|
| 408 |
27P Study of tumor mutational variation measured by NGS in patients with BRAF-mutated metastatic colorectal cancer undergoing surgery after prior systemic treatment
|
Alsar, J. Soto
|
|
|
36 |
S1 |
p. S16
|
artikel
|
| 409 |
58P Surgery versus ablation for colorectal liver metastases: A tertiary referral hospital experience
|
Verdasca, F.R.
|
|
|
36 |
S1 |
p. S32
|
artikel
|
| 410 |
227P Surgical outcomes post-total mesorectal excision in patients with locally advanced rectal cancer undergoing total neoadjuvant treatment with short-course radiotherapy followed by chemo-immunotherapy: Data from the phase II Averectal trial
|
Shamseddine, A.I.
|
|
|
36 |
S1 |
p. S91
|
artikel
|
| 411 |
302P Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer
|
Gao, S.
|
|
|
36 |
S1 |
p. S118-S119
|
artikel
|
| 412 |
77P Survival outcomes and molecular characteristics of early-onset colorectal cancer patients (EOCRC): A multiracial cohort
|
Wong, E.Y.T.
|
|
|
36 |
S1 |
p. S40
|
artikel
|
| 413 |
216P Survival outcomes in basaloid squamous cell carcinoma of the anorectal region: A Surveillance, Epidemiology, and End Results (SEER) database analysis
|
Arunachalam, J.
|
|
|
36 |
S1 |
p. S87
|
artikel
|
| 414 |
41P Switch from cetuximab (CET) to panitumumab (PANI) during encorafenib (ENCO)-based therapy in BRAF V600E mutated metastatic colorectal cancer (mCRC): An international multicenter analysis from the AGEO group
|
Gandini, A.
|
|
|
36 |
S1 |
p. S25-S26
|
artikel
|
| 415 |
124P Synthetic lethality of CBM signalosome inhibition for KRAS-mutant colorectal cancers
|
Yao, Y.
|
|
|
36 |
S1 |
p. S56
|
artikel
|
| 416 |
315P Targeted inhibition of exportin-1 enhances anticancer efficacy and augments therapeutic outcomes in pancreatic ductal adenocarcinoma by modulation of LAMC2/KRAS/ERK1/2/AKT signaling network via hsa-miR-193b-3p
|
Singh, A.
|
|
|
36 |
S1 |
p. S122
|
artikel
|
| 417 |
200P Targeting hypoxia-inducible factor 1α to suppress hypoxia-mediated progression and invasion of hepatocellular carcinoma
|
Payo-Serafín, T.
|
|
|
36 |
S1 |
p. S81
|
artikel
|
| 418 |
30P T cell cancer cell interaction in prediction of response to EGFR-, VEGF-inhibitors or no biologics in first-line treatment of metastatic colorectal cancer (mCRC) patients
|
Osterlund, P.J.
|
|
|
36 |
S1 |
p. S17-S18
|
artikel
|
| 419 |
176P Tegavivint, a downstream Wnt/β-catenin inhibitor: Interim results from a phase I/II trial in advanced hepatocellular carcinoma (aHCC)
|
Li, D.
|
|
|
36 |
S1 |
p. S74
|
artikel
|
| 420 |
298P The effect of the gut microbiome on tumour response to anti-cancer treatment in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC): A prospective study
|
Robinson, M.
|
|
|
36 |
S1 |
p. S117
|
artikel
|
| 421 |
198P The impact of HLA-E and IFNL4 genes on hepatocellular carcinoma (HCC) development and progression in hepatitis C virus (HCV)-infected patients (VERYMARKERS Study)
|
Foltran, L.
|
|
|
36 |
S1 |
p. S81
|
artikel
|
| 422 |
326P The journey of patients (pts) with biliary tract cancers (BTCs): Identifying challenges and unmet needs
|
Corallo, S.
|
|
|
36 |
S1 |
p. S127
|
artikel
|
| 423 |
481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group
|
Dreikhausen, L.
|
|
|
36 |
S1 |
p. S181-S182
|
artikel
|
| 424 |
192P The prognostic value of choline PET/CT in the initial assessment of patients with hepatocellular carcinoma
|
Couvert, H.P.V.
|
|
|
36 |
S1 |
p. S79
|
artikel
|
| 425 |
291P The regulatory roles of neutrophils in pancreatic ductal adenocarcinoma
|
Khan, M.
|
|
|
36 |
S1 |
p. S114-S115
|
artikel
|
| 426 |
299P The role of OnkoTEV, PLR and CA19.9 in predicting thromboembolic events in pancreatic cancer patients: Retrospective 5-year analysis in a Portuguese center
|
Fernandes, C.L.
|
|
|
36 |
S1 |
p. S117-S118
|
artikel
|
| 427 |
416P The shifting global landscape of interventional clinical trials in gastric and gastroesophageal cancers: A ClinicalTrials.gov analysis
|
Sargsyan, A.
|
|
|
36 |
S1 |
p. S163
|
artikel
|
| 428 |
426P The strategy of planned discontinuation of oxaliplatin for advanced gastric cancer treated with nivolumab plus chemotherapy: A multi-center retrospective study
|
Furuta, M.
|
|
|
36 |
S1 |
p. S167
|
artikel
|
| 429 |
336P The use of regorafenib in cholangiocarcinoma: A real-world data (RWD) review
|
Browne, R.
|
|
|
36 |
S1 |
p. S131-S132
|
artikel
|
| 430 |
328P Time toxicity (TT) associated with first-line treatment (1L) in patients (pts) with advanced biliary tract cancer (aBTC)
|
Okano, N.
|
|
|
36 |
S1 |
p. S128
|
artikel
|
| 431 |
287P To biopsy or not to biopsy: A predictive model for liquid biopsy in advanced pancreatic cancer
|
Attieh, F.
|
|
|
36 |
S1 |
p. S112-S113
|
artikel
|
| 432 |
232P Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Is practice matching the evidence? Real-world experience from Uruguay
|
Fontes, S.
|
|
|
36 |
S1 |
p. S93
|
artikel
|
| 433 |
233P Total neoadjuvant therapy (TNT) with RAPIDO in rectal adenocarcinomas: Real-world experience
|
Shah, S.K.
|
|
|
36 |
S1 |
p. S93
|
artikel
|
| 434 |
84P Towards a tailored care program: Exploring the characteristics of EOCRC patients at a comprehensive cancer center in Germany
|
Kaunath, K.
|
|
|
36 |
S1 |
p. S43
|
artikel
|
| 435 |
171P Transarterial chemoembolization (TACE) with or without anti-PD1/PD-L1 systemic therapy in unresectable hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Kim, H.J.S.
|
|
|
36 |
S1 |
p. S72
|
artikel
|
| 436 |
185P Transarterial radioembolization in hepatocellular carcinoma patients with curative intent: A pooled, retrospective analysis of two studies in Europe
|
Arnold, D.
|
|
|
36 |
S1 |
p. S77
|
artikel
|
| 437 |
279P Transcriptomic analysis of homologous recombination repair (HRR) genes in BRCA1/2 and PALB2 wild-type (wt) metastatic pancreatic cancer (mPC) suggests potential platinum sensitivity
|
Zheng-Lin, B.
|
|
|
36 |
S1 |
p. S109-S110
|
artikel
|
| 438 |
339P Treatment of cholangiocarcinomas: Beyond second-line therapy
|
Mihele, A.B.
|
|
|
36 |
S1 |
p. S133
|
artikel
|
| 439 |
361P Treatment patterns and survival outcomes of patients with gallbladder cancer (GBC): A real-world comparative study over two decades
|
Quitadamo, M.P.F.
|
|
|
36 |
S1 |
p. S141
|
artikel
|
| 440 |
62P Trifluridine/tipiracil plus bevacizumab (TTB) versus regorafenib (R) in refractory advanced colorectal cancer patients: A real-word evidence efficacy study
|
Pascual, J. Rodriguez
|
|
|
36 |
S1 |
p. S34
|
artikel
|
| 441 |
80P Tumor immune microenvironment in young, multi-ethnic colorectal cancer patients
|
Salem, M.E.
|
|
|
36 |
S1 |
p. S41
|
artikel
|
| 442 |
317P Tumor-microenvironment-on-chip: A real-time window into immunotherapy efficacy under heterogeneity
|
Lin, C-M.
|
|
|
36 |
S1 |
p. S123
|
artikel
|
| 443 |
412P Tumour-free lymph node microarchitecture associates with tumour location-specific survival in oesophagogastric cancer: Results from the OE05 and ST03 trials
|
Budginaite, E.
|
|
|
36 |
S1 |
p. S161-S162
|
artikel
|
| 444 |
81P Tumour microbiome and immune dysregulation in early-onset colorectal cancer
|
Purcell, R.V.
|
|
|
36 |
S1 |
p. S42
|
artikel
|
| 445 |
487P Uncharted territory: Efficacy and safety of lower dose intensity immunotherapy in mismatch-repair-deficient and microsatellite instability-high gastrointestinal cancers: Real world data
|
Shamseddine, A.I.
|
|
|
36 |
S1 |
p. S184
|
artikel
|
| 446 |
33P Unveiling the patterns: Clinical and molecular traits of brain metastases (BM) in colorectal cancer (CRC)
|
Pena, M. Balsa
|
|
|
36 |
S1 |
p. S19
|
artikel
|
| 447 |
225P Updated results and first biomarker analysis of a phase II trial combining nivolumab (nivo) and total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC) (CA209-8M4)
|
Brenner, B.
|
|
|
36 |
S1 |
p. S90
|
artikel
|
| 448 |
100P Vascular endothelial growth factor in colorectal cancer progression and 5, 10 and 15 year survival
|
Wilson, D.
|
|
|
36 |
S1 |
p. S48
|
artikel
|
| 449 |
242P Watch-and-wait vs direct surgery in low rectal cancer: A comparative outcome analysis
|
Pereira, M.Q.
|
|
|
36 |
S1 |
p. S95-S96
|
artikel
|
| 450 |
438P Young-onset gastric adenocarcinoma: A population-based analysis
|
Deac, O.
|
|
|
36 |
S1 |
p. S171
|
artikel
|
| 451 |
493P Young-onset gastrointestinal cancer patients enrolled in phase I clinical trials: The experience from Gustave Roussy Cancer Center
|
Caraballo, I. Gonzalez
|
|
|
36 |
S1 |
p. S185-S186
|
artikel
|
| 452 |
248P Young-onset rectal cancer (YORC): A descriptive tertiary center analysis
|
Schraepen, C.
|
|
|
36 |
S1 |
p. S97
|
artikel
|
| 453 |
491P Zongertinib in HER2-altered gastrointestinal cancers: Preclinical activity and clinical findings from a phase Ia study
|
Yoh, K.
|
|
|
36 |
S1 |
p. S185
|
artikel
|
| 454 |
Table of Contents
|
|
|
|
36 |
S1 |
p. iv
|
artikel
|
| 455 |
477TiP A randomised phase II study of zimberelimab ± domvanalimab immunotherapy in resectable mismatch repair deficient (dMMR) gastric and gastroesophageal junctional (G/GOJ) adenocarcinoma (ZODIAC)
|
Keogh, G.A.
|
|
|
36 |
S1 |
p. S179-S180
|
artikel
|
| 456 |
385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3
|
Goyal, L.
|
|
|
36 |
S1 |
p. S148
|
artikel
|
| 457 |
386TiP Gemcitabine and nab-paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The phase III PANThEON trial
|
Sciortino, C.
|
|
|
36 |
S1 |
p. S149
|
artikel
|
| 458 |
146TiP MIRACLE3: Phase II study of ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases
|
Li, X.
|
|
|
36 |
S1 |
p. S61
|
artikel
|
| 459 |
384TiP Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial
|
Mercade, T. Macarulla
|
|
|
36 |
S1 |
p. S147-S148
|
artikel
|
Tijdschrift beschrijving